Zacks Research Has Bullish Forecast for Clorox Q4 Earnings

The Clorox Company (NYSE:CLX) – Equities researchers at Zacks Research raised their Q4 2025 earnings per share (EPS) estimates for Clorox in a report issued on Monday, May 19th. Zacks Research analyst R. Department now forecasts that the company will post earnings of $2.23 per share for the quarter, up from their prior forecast of $2.14. The consensus estimate for Clorox’s current full-year earnings is $7.15 per share. Zacks Research also issued estimates for Clorox’s Q1 2026 earnings at $1.52 EPS, Q2 2026 earnings at $1.51 EPS, Q3 2026 earnings at $1.57 EPS, FY2026 earnings at $6.71 EPS, Q1 2027 earnings at $1.62 EPS, Q2 2027 earnings at $1.71 EPS and Q3 2027 earnings at $1.70 EPS.

Other equities analysts also recently issued research reports about the company. Royal Bank of Canada reiterated a “sector perform” rating and set a $150.00 price objective on shares of Clorox in a research report on Thursday, January 30th. DA Davidson reduced their price objective on Clorox from $171.00 to $169.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Barclays reduced their price objective on Clorox from $134.00 to $129.00 and set an “underweight” rating on the stock in a research report on Wednesday, May 7th. Morgan Stanley reduced their price objective on Clorox from $165.00 to $150.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Finally, Wells Fargo & Company reduced their price objective on Clorox from $145.00 to $142.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $151.23.

Clorox Stock Performance

Shares of NYSE:CLX opened at $130.93 on Wednesday. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60. The business’s 50 day moving average price is $139.91 and its 200-day moving average price is $152.60. The firm has a market capitalization of $16.14 billion, a PE ratio of 35.77, a P/E/G ratio of 2.62 and a beta of 0.60. Clorox has a 1 year low of $127.60 and a 1 year high of $171.37.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). The firm had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a return on equity of 316.87% and a net margin of 6.38%. The business’s revenue was down 8.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.71 earnings per share.

Clorox Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 9th. Shareholders of record on Wednesday, April 23rd were given a $1.22 dividend. The ex-dividend date of this dividend was Wednesday, April 23rd. This represents a $4.88 dividend on an annualized basis and a yield of 3.73%. Clorox’s dividend payout ratio is currently 87.61%.

Insider Buying and Selling at Clorox

In other news, Director Pierre R. Breber acquired 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The shares were purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the acquisition, the director now owns 4,000 shares of the company’s stock, valued at $546,280. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 0.57% of the company’s stock.

Institutional Investors Weigh In On Clorox

Several institutional investors and hedge funds have recently modified their holdings of CLX. Brooklyn Investment Group raised its holdings in shares of Clorox by 163.8% in the 4th quarter. Brooklyn Investment Group now owns 153 shares of the company’s stock valued at $25,000 after buying an additional 95 shares during the period. Redwood Park Advisors LLC purchased a new stake in shares of Clorox in the 4th quarter valued at $26,000. Millstone Evans Group LLC purchased a new stake in shares of Clorox in the 4th quarter valued at $31,000. Wood Tarver Financial Group LLC purchased a new stake in shares of Clorox in the 4th quarter valued at $31,000. Finally, Asset Planning Inc purchased a new stake in shares of Clorox in the 4th quarter valued at $32,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.